Exelixis Inc. (EXEL)
Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
EXEL vs. ARGX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.
Product Performance, Big Money Lift Exelixis
Shares of Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, boosted by Big Money inflows.
Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects
Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis: A Notable Quarter
Exelixis just delivered a strong Q1 beat, raised 2025 guidance, and continues to benefit from robust Cabometyx sales and share buybacks. The company is transitioning to zanzalintinib as its next flagship drug, but pivotal trial success remains uncertain, and skepticism persists among analysts. The company has a rock-solid balance sheet with some $1.75 billion in cash and no long-term debt.
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.
Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morrissey - President and Chief Executive Officer Christopher Senner - Executive Vice President and Chief Financial Officer P.J. Haley - Executive Vice President, Commercial Amy Peterson - Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer Dana Aftab - Executive Vice President, Discovery and Translational Research and Chief Scientific Officer Conference Call Participants Michael Schmidt - Guggenheim Asthika Goonewardene - Truist Sean Laaman - Morgan Stanley Silvan Tuerkcan - Citizens Yaron Werber - TD Cowen Chi Fong - Bank of America Securities Akash Tewari - Jefferies Eva Fortea-Verdejo - Wells Fargo Andy Hsieh - William Blair Eason Lee - Leerink Partners Cheng Li - Oppenheimer Ashwani Verma - UBS Peter Lawson - Barclays Felix Ampomah - Stephens Operator Good day, ladies and gentlemen, and welcome to the Exelixis First Quarter 2025 Financial Results Conference Call.
Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
